Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
We are studying this investigational drug treatment, comparing it with placebo, to evaluate
whether it is effective in reducing the number of MRI lesions with a minimum number of side
effects. The investigational drug will be administered in the clinic weekly for 5 injections
(induction phase) then monthly for 8 additional injections (maintenance phase).
Approximately 150 male and female patients (100 active and 50 placebo), aged 18 to 55 years,
with relapsing MS and at least one but no more than 10 total Gd-enhancing lesions on cranial
MRI scans during the run-in phase will be randomized into this study.